Literature DB >> 24859877

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Kazuyuki Murase1, Haesook T Kim2, O R Gregory Bascug3, Yutaka Kawano1, Jeremy Ryan1, Ken-ichi Matsuoka4, Matthew S Davids1, John Koreth1, Vincent T Ho1, Corey Cutler1, Philippe Armand1, Edwin P Alyea1, Bruce R Blazar5, Joseph H Antin1, Robert J Soiffer1, Anthony Letai1, Jerome Ritz6.   

Abstract

CD4 regulatory T cells play a critical role in establishment of immune tolerance and prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. The recovery and maintenance of regulatory T cells is dependent on homeostatic factors including the generation of naïve regulatory T cells from hematopoietic precursor cells, the proliferation and expansion of mature regulatory T cells, and the survival of regulatory T cells in vivo. In this study, quantitation of mitochondrial apoptotic priming was used to compare susceptibility of regulatory T cells, conventional CD4 T cells and CD8 T cells to intrinsic pathway apoptosis in 57 patients after allogeneic hematopoietic stem cell transplantation and 25 healthy donors. In healthy donors, regulatory T cells are more susceptible to mitochondrial priming than conventional T cells. Mitochondrial priming is increased after hematopoietic stem cell transplantation in all T-cell subsets and particularly in patients with chronic graft-versus-host disease. Regulatory T cells express high levels of CD95 and are also more susceptible than conventional T cells to apoptosis through the extrinsic pathway. However, CD95 expression and extrinsic pathway apoptosis is not increased after hematopoietic stem cell transplantation. Decreased expression of BCL2 and increased expression of BIM, a mitochondrial cell death activator protein, in regulatory T cells contributes to increased mitochondrial priming in this T-cell subset but additional factors likely contribute to increased mitochondrial priming following hematopoietic stem cell transplantation. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24859877      PMCID: PMC4562540          DOI: 10.3324/haematol.2014.104166

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  64 in total

1.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Authors:  Huihui Ma; Caisheng Lu; Judith Ziegler; Ailing Liu; Antonia Sepulveda; Hideho Okada; Suzanne Lentzsch; Markus Y Mapara
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

2.  Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.

Authors:  Kaifeng Lisa Lin; LeShara M Fulton; Matthew Berginski; Michelle L West; Nicholas A Taylor; Timothy P Moran; James M Coghill; Bruce R Blazar; James E Bear; Jonathan S Serody
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

3.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.

Authors:  Kathrin Rieger; Christoph Loddenkemper; Jochem Maul; Thomas Fietz; Daniel Wolff; Harald Terpe; Beate Steiner; Erika Berg; Stephan Miehlke; Martin Bornhäuser; Thomas Schneider; Martin Zeitz; Harald Stein; Eckhard Thiel; Rainer Duchmann; Lutz Uharek
Journal:  Blood       Date:  2005-11-08       Impact factor: 22.113

4.  Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells.

Authors:  Eva-Maria Weiss; Angelika Schmidt; Diana Vobis; Natalio Garbi; Katharina Lahl; Christian T Mayer; Tim Sparwasser; Andreas Ludwig; Elisabeth Suri-Payer; Nina Oberle; Peter H Krammer
Journal:  J Immunol       Date:  2011-07-11       Impact factor: 5.422

5.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

6.  Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors:  Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

7.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

8.  The role of regulatory T cells in the biology of graft versus host disease.

Authors:  Amy J Beres; William R Drobyski
Journal:  Front Immunol       Date:  2013-06-24       Impact factor: 7.561

9.  Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood.

Authors:  Dan Hu; Howard L Weiner; Jerome Ritz
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation.

Authors:  Emanuela I Sega; Dennis B Leveson-Gower; Mareike Florek; Dominik Schneidawind; Richard H Luong; Robert S Negrin
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  11 in total

1.  PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Authors:  Takeru Asano; Yusuke Meguri; Takanori Yoshioka; Yuriko Kishi; Miki Iwamoto; Makoto Nakamura; Yasuhisa Sando; Hideo Yagita; John Koreth; Haesook T Kim; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Yoshinobu Maeda; Mitsune Tanimoto; Jerome Ritz; Ken-Ichi Matsuoka
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

2.  BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.

Authors:  Tomohiro Kubo; Yutaka Kawano; Nobuaki Himuro; Shintaro Sugita; Yasushi Sato; Kazuma Ishikawa; Kohichi Takada; Kazuyuki Murase; Koji Miyanishi; Tsutomu Sato; Rishu Takimoto; Masayoshi Kobune; Takayuki Nobuoka; Koichi Hirata; Tetsuji Takayama; Mitsuru Mori; Tadashi Hasegawa; Junji Kato
Journal:  Gastric Cancer       Date:  2015-10-20       Impact factor: 7.370

Review 3.  Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.

Authors:  Ken-Ichi Matsuoka
Journal:  Int J Hematol       Date:  2017-12-12       Impact factor: 2.490

4.  Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.

Authors:  Masahiro Hirakawa; Tiago R Matos; Hongye Liu; John Koreth; Haesook T Kim; Nicole E Paul; Kazuyuki Murase; Jennifer Whangbo; Ana C Alho; Sarah Nikiforow; Corey Cutler; Vincent T Ho; Philippe Armand; Edwin P Alyea; Joseph H Antin; Bruce R Blazar; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  JCI Insight       Date:  2016-11-03

5.  Characteristics of regulatory T-cell populations before and after Ty21a typhoid vaccination in children and adults.

Authors:  Mark E Rudolph; Monica A McArthur; Laurence S Magder; Robin S Barnes; Wilbur H Chen; Marcelo B Sztein
Journal:  Clin Immunol       Date:  2019-04-04       Impact factor: 3.969

Review 6.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

7.  Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

Authors:  Edouard Forcade; Haesook T Kim; Corey Cutler; Kathy Wang; Ana C Alho; Sarah Nikiforow; Vincent T Ho; John Koreth; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2016-03-04       Impact factor: 22.113

8.  Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Authors:  Ana C Alho; Haesook T Kim; Marie J Chammas; Carol G Reynolds; Tiago R Matos; Edouard Forcade; Jennifer Whangbo; Sarah Nikiforow; Corey S Cutler; John Koreth; Vincent T Ho; Philippe Armand; Joseph H Antin; Edwin P Alyea; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

9.  Current Concepts and Advances in Graft-Versus-Host Disease Immunology.

Authors:  Geoffrey R Hill; Brian C Betts; Victor Tkachev; Leslie S Kean; Bruce R Blazar
Journal:  Annu Rev Immunol       Date:  2021-01-11       Impact factor: 28.527

Review 10.  Hematopoietic Stem Cell Niche During Homeostasis, Malignancy, and Bone Marrow Transplantation.

Authors:  Yan Man; Xiangmei Yao; Tonghua Yang; Yajie Wang
Journal:  Front Cell Dev Biol       Date:  2021-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.